Chief Medical Officer, Slate Medicines
Appears in 1 story
Leading clinical strategy for SLTE-1009
Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal backed by a $245 million private placement.
Updated 6 minutes ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
